FINWIRES · TerminalLIVE
FINWIRES

Microsoft, Mayo Clinic Collaborate on Clinical AI Model

By

Microsoft (MSFT) and Mayo Clinic announced a collaboration to develop a frontier AI model tailored for healthcare, aiming to support clinical reasoning, earlier diagnoses and more personalized treatment decisions, according to a statement Tuesday.

The highly advanced model combines Mayo's de-identified clinical data with Microsoft's AI and cloud capabilities and will initially be deployed within Mayo's clinical environment, according to the statement.

The model will be owned by Mayo Clinic and later made available globally through Microsoft's Azure Foundry APIs. The collaboration is intended to expand access to Mayo's clinical expertise and support care teams in complex decision-making, according to the statement.

Price: $441.88, Change: $-18.64, Percent Change: -4.05%

Related Articles

Wire

Dollar General Posts 'Solid' Q1, Truist Says

Dollar General (DG) posted a "solid" Q1 performance, including a 2.0% growth in comparable sales, Truist said in a note Tuesday.The report said the firm is benefitting among others from trade-in activity by higher-income consumers, incremental sales from delivery business, and the comparable lift from remodels, while lower-income consumers remain under pressure.Truist analysts said they are "modestly" raising their 2026/2027 EPS estimates, partly from a lower tax rate."We think DG is "interesting" at current levels, but Walmart (WMT, Buy) competition + economic pressures on their core customer keep us cautious," the note said.Truist raised its price target to $114 from $109 while maintaining its hold rating.Price: $108.06, Change: $-1.88, Percent Change: -1.71%

$DG
Wire

Starwood Property Trust Shares Rise After UBS Upgrade

Starwood Property Trust (STWD) shares rose 1.8% in Tuesday trading after UBS upgraded the stock to buy from neutral and raised the price target to $20 from $19.50.Trading volume stood at 2.5 million shares, compared with a daily average of about 3.1 million.Price: $17.08, Change: $+0.28, Percent Change: +1.67%

$STWD
Wire

Celcuity Says Gedatolisib Outperforms Novartis' Alpelisib Plus Fulvestrant in Phase 3 Trial

Celcuity (CELC) said Tuesday that detailed results from the Phase 3 Viktoria-1 trial showed its investigational breast cancer treatment gedatolisib outperformed Novartis' (NVS) alpelisib plus fulvestrant in patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer.Celcuity said the gedatolisib plus fulvestrant and palbociclib, or gedatolisib-triplet reduced the risk of disease progression or death by 50% compared with alpelisib plus fulvestrant, and nearly doubled median progression-free survival to 11.1 months from 5.6 months, while gedatolisib plus fulvestrant, or gedatolisib-doublet extended progression-free survival to 11.3 months, with objective response rates of 48.9% and 35.7%, respectively.The gedatolisib triplet and doublet regimens were generally well tolerated, with mostly low-grade treatment-related adverse events, while overall survival data, a key secondary endpoint, showed promising trends but remain immature. Celcuity plans to submit the data to the US Food and Drug Administration as a supplemental new drug application.Shares of Celcuity were down more than 25% in Tuesday trading.Price: $91.65, Change: $-31.31, Percent Change: -25.46%

$CELC$NVS